Compare FUND & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | VNDA |
|---|---|---|
| Founded | 1988 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.4M | 289.0M |
| IPO Year | N/A | 2006 |
| Metric | FUND | VNDA |
|---|---|---|
| Price | $8.62 | $6.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 32.5K | ★ 1.3M |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | $8.33 | ★ N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $6.75 | $3.81 |
| 52 Week High | $8.47 | $6.88 |
| Indicator | FUND | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 64.60 |
| Support Level | $8.65 | $6.15 |
| Resistance Level | $8.95 | $6.88 |
| Average True Range (ATR) | 0.12 | 0.41 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 50.91 | 73.65 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.